MX2022001416A - Metodo para mejorar la accion antimicrobiana de los antibioticos administrados sistemicamente. - Google Patents

Metodo para mejorar la accion antimicrobiana de los antibioticos administrados sistemicamente.

Info

Publication number
MX2022001416A
MX2022001416A MX2022001416A MX2022001416A MX2022001416A MX 2022001416 A MX2022001416 A MX 2022001416A MX 2022001416 A MX2022001416 A MX 2022001416A MX 2022001416 A MX2022001416 A MX 2022001416A MX 2022001416 A MX2022001416 A MX 2022001416A
Authority
MX
Mexico
Prior art keywords
antibiotic
target tissue
antimicrobial action
enhancing
effect
Prior art date
Application number
MX2022001416A
Other languages
English (en)
Inventor
Sakari Nikinmaa
Juha Rantala
Tommi Pätilä
Original Assignee
Koite Health Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koite Health Oy filed Critical Koite Health Oy
Publication of MX2022001416A publication Critical patent/MX2022001416A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

Antibiótico para usarse en un método que comprende la administración sistémica de un antibiótico fotosensible a un sujeto que tiene una infección microbiana en un tejido blanco para proporcionar una concentración plasmática del antibiótico en el sujeto; permitir que la concentración plasmática o tisular del antibiótico aumente hasta un nivel predeterminado; y someter el tejido blanco a una terapia fotodinámica para aumentar la acción antimicrobiana del antibiótico en el tejido blanco. Con la activación por luz puede mejorarse la eficacia del antibiótico fotosensibilizante, ampliarse el espectro del efecto microbiano e incluso puede obtenerse un efecto antiviral. En general, la presente invención puede explotarse cuando existe una necesidad de mejorar el efecto antimicrobiano local de antibióticos.
MX2022001416A 2019-08-02 2020-08-03 Metodo para mejorar la accion antimicrobiana de los antibioticos administrados sistemicamente. MX2022001416A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20195661 2019-08-02
PCT/FI2020/050514 WO2021023915A1 (en) 2019-08-02 2020-08-03 Method of enhancing the antimicrobial action of systemically administered antibiotics

Publications (1)

Publication Number Publication Date
MX2022001416A true MX2022001416A (es) 2022-05-26

Family

ID=72145413

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001416A MX2022001416A (es) 2019-08-02 2020-08-03 Metodo para mejorar la accion antimicrobiana de los antibioticos administrados sistemicamente.

Country Status (9)

Country Link
US (1) US20210030874A1 (es)
EP (1) EP4007582A1 (es)
JP (1) JP2022543103A (es)
KR (1) KR20220061106A (es)
CN (1) CN114641313A (es)
AU (1) AU2020326320A1 (es)
CA (1) CA3149611A1 (es)
MX (1) MX2022001416A (es)
WO (1) WO2021023915A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI130369B (en) * 2018-10-26 2023-07-28 Koite Health Oy A method for treating biological surfaces
FI130810B1 (en) * 2020-02-27 2024-03-27 Koite Health Oy Procedures and kits for the treatment of skin infections
ES2927913B2 (es) * 2021-05-07 2023-07-27 Univ Murcia Composición que comprende una combinación de las furanocumarinas psoraleno y angelicina y su uso en terapia
CN116482084A (zh) * 2023-02-13 2023-07-25 上海索昕生物科技有限公司 用于光激化学发光检测的感光微球

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089750A2 (en) * 2001-01-19 2002-11-14 Advanced Photodynamic Technologies, Inc. Apparatus and method of photodynamic eradication of organisms utilizing pyrrolnitrin
US7753943B2 (en) * 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
US20050059731A1 (en) * 2003-09-16 2005-03-17 Ceramoptec Industries, Inc. Erythrosin-based antimicrobial photodynamic therapy compound and its use
EP2049105A4 (en) * 2006-07-27 2022-03-30 biolitec Unternehmensbeteiligungs II AG ANTIMICROBIAL PHOTODYNAMIC THERAPY
GB2454652A (en) * 2007-11-01 2009-05-20 Mohamed Abdelhafez El-Far Photodynamic therapy device including a plurality of light sources
EP2516003A1 (en) * 2009-12-21 2012-10-31 Colgate-Palmolive Company Kit containing photosensitizing dyes
CN108697750A (zh) * 2015-10-01 2018-10-23 光动力公司 新型虎杖提取物及它们作为光动力灭活剂的用途
CN109091685A (zh) * 2018-08-10 2018-12-28 北京市眼科研究所 一种对角膜炎提取细菌病原体的灭活方法
FI130369B (en) * 2018-10-26 2023-07-28 Koite Health Oy A method for treating biological surfaces

Also Published As

Publication number Publication date
KR20220061106A (ko) 2022-05-12
CN114641313A (zh) 2022-06-17
JP2022543103A (ja) 2022-10-07
WO2021023915A1 (en) 2021-02-11
US20210030874A1 (en) 2021-02-04
EP4007582A1 (en) 2022-06-08
CA3149611A1 (en) 2021-02-11
AU2020326320A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
MX2022001416A (es) Metodo para mejorar la accion antimicrobiana de los antibioticos administrados sistemicamente.
Alumutairi et al. Mild magnetic nanoparticle hyperthermia enhances the susceptibility of Staphylococcus aureus biofilm to antibiotics
Hönigsmann History of phototherapy in dermatology
MX2023006353A (es) Sistema ultravioleta para el tratamiento intracorporal.
CY1116463T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
MX2020009773A (es) Terapia de combinacion.
DK1267897T3 (da) Behandling af kongestiv hjerteinsuffiens med forbehandlet autologt blod
Rosa et al. Effectiveness of antimicrobial photodynamic therapy using a 660 nm laser and methyline blue dye for inactivating Staphylococcus aureus biofilms in compact and cancellous bones: An in vitro study
BR112021016833A2 (pt) Compostos com atividade indutora de ferroptose e métodos de seu uso
MX2020000830A (es) Metodos y aparato para suministrar radiacion electromagnetica no ultravioleta terapeutica para inactivar agentes infecciosos.
NO20032027L (no) Effektive antitumorbehandlinger
WO2021174107A8 (en) Soluble ace2 variants and uses therefor
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2022003190A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
MX2021013447A (es) Composiciones y procedimientos para el tratamiento de enfermedades oculares.
Tariq et al. Photodynamic therapy: A rational approach toward COVID-19 management
WO2022053993A3 (en) Treatments for sars-cov-2 infection (covid-19)
EP2542305A4 (en) ADVANCED ANTIMICROBIAL PDT
RU2013104381A (ru) Лечение отслойки васкуляризированного пигментного эпителия терапевтическим средством против vegf
MX2022010093A (es) Tafoxiparina para el tratamiento de la preeclampsia.
AU2020327022A8 (en) Method of treating cancer
EA202192234A1 (ru) Комбинированная терапия для применения в лечении рака
WO2023009834A3 (en) Methods of treating cancer
BR112022001814A2 (pt) Métodos de tratamento de câncer multifocal
MX2022011844A (es) Terapia combinada con un inhibidor de idh mutante.